上海市免疫学研究所成立于 1979 年，隶属于上海交通大学医学院，是由上海市和上海交通大学医学院共 建的我国第一个免疫学研究机构。目前，免疫所现有课题组长 24 人，其中包括国家海外高层次人才计划 12 人，国家杰出青年科学基金获得者 3 人，国家优秀青年基金获得者 5 人。所内研究团队按照"创新突 破"和"加强转化"的总体发展战略，以基础和临床科学问题为导向，对接国家战略需求，持续承担国家和地 方科研攻关项目。近三年原创性科研工作相继在领域内顶尖或知名期刊杂志 Cell 、 Nature、 Nature Immunology 、 Cell Metabolism 、 Cell Stem Cell 、 Science Immunology 、 Science Translational Medicine 、 PNAS 、 JEM 等发表，形成了一批具有国际影响力的突破性成果。此外，上海市免疫学研究 所与国际顶级免疫学机构以及免疫生物学家保持密切交流，与包括美国、法国、英国、澳大利亚、新加坡 以及中国香港、中国台湾和大陆地区在内的近五十所知名院校、研究机构开展了积极深入的合作交流，率 先建立海外顶尖专家指导制度及 ...

Core Viewpoint - The collaboration between Dechra Pharmaceuticals-B (06996) and Junshi Biosciences aims to explore the synergistic potential of their respective drugs, ATG-037 and JS207, in treating tumor patients in mainland China, particularly in the context of overcoming resistance to immune checkpoint inhibitors (CPI) [1]. Group 1: Company Developments - Dechra Pharmaceuticals-B's stock rose over 6%, reaching HKD 3.66 with a trading volume of HKD 13.326 million [1]. - The company announced a clinical collaboration agreement with Junshi Biosciences to jointly investigate the combination treatment of ATG-037, an oral CD73 small molecule inhibitor, and JS207, a dual-specific antibody targeting PD-1/VEGF [1]. Group 2: Clinical Insights - The collaboration aims to address the significant clinical challenge of resistance to immune checkpoint inhibitors, with ATG-037 showing strong potential to reverse this resistance in Phase I trials when used in combination with CPIs [1]. - The partnership intends to validate the synergistic effects of the two innovative drugs through a "triple-axis" strategy of "immunotherapy + anti-angiogenesis + adenosine inhibition," aiming to break through the current efficacy ceiling of immunotherapy and significantly extend overall survival (OS) for cancer patients [1].

Group 1 - The core point of the article is that 德琪医药-B (06996) has seen a stock increase of over 6%, currently trading at 3.66 HKD with a transaction volume of 13.32 million HKD [1] - The company announced a clinical collaboration agreement with 君实生物 to explore the combined treatment potential of its ATG-037 (oral CD73 small molecule inhibitor) and 君实生物's JS207 (anti-PD-1/VEGF bispecific antibody) in cancer patients in mainland China [1] - The collaboration aims to validate the synergistic effects of the two innovative drugs and to overcome the current efficacy ceiling of immunotherapy through a "triple-axis" strategy of "immunotherapy + anti-angiogenesis + adenosine inhibition," ultimately aiming to significantly extend overall survival (OS) for cancer patients [1]

Core Viewpoint - The collaboration between Deqi Pharmaceutical and Junshi Biosciences aims to explore the synergistic potential of their respective drugs, ATG-037 and JS207, in treating tumor patients in mainland China, particularly in the context of overcoming resistance to immune checkpoint inhibitors [1] Group 1: Company Developments - Deqi Pharmaceutical's stock rose by 6.4%, reaching HKD 3.66, with a trading volume of HKD 13.326 million [1] - The company announced a clinical collaboration agreement with Junshi Biosciences to jointly investigate the combination therapy of ATG-037, an oral CD73 small molecule inhibitor, and JS207, a dual-specific antibody targeting PD-1/VEGF [1] Group 2: Industry Context - The collaboration addresses a significant clinical challenge where resistance to immune checkpoint inhibitors (CPI) has become prevalent [1] - ATG-037 has demonstrated strong potential in reversing resistance in Phase I trials when used in combination with CPIs [1] - The partnership aims to validate the synergistic effects of the two innovative drugs and seeks to extend overall survival (OS) for cancer patients through a "triple-axis" strategy involving "immunotherapy + anti-angiogenesis + adenosine inhibition" [1]

撰文丨王聪 编辑丨王多鱼 排版丨水成文 肿瘤微环境 （TME） 是有效免疫治疗的主要障碍，然而，用于剖析肿瘤微环境空间复杂性及其背景免疫调 节剂的高通量扰动图谱方法，目前仍显不足。 在这项最新研究中，研究团队开发了肿瘤免疫微环境的 CRISPR-激光捕获显微切割整合图谱—— CLIM- TIME （ C RISPR- L aser-captured microdissection I ntegration M apping of T umor I mmune M icro e nvironment ） ，这是一个可扩展平台，将 CRISPR 筛选与转移性肿瘤的 激光显微切割 （ LCM ） 相结合，用于转录组学、去卷积和免疫荧光分析。 CLIM-TIME 能够实现空间分辨的 肿瘤抑制基因 （ tumor suppressor gene， TSG） 缺失如何重塑肿 瘤微环境 （TME） 并调控免疫反应的图谱绘制。利用 CLIM-TIME ，研究团队确定了 七种 不同的肿瘤微 环境 （TME） 亚型，揭示出 DNA 修复和多梳抑制复合物 （PRC） 肿瘤抑制基因 （TSG） 的缺失与对 T 细胞疗法敏感的免疫浸润 ...

Core Viewpoint - The announcement highlights the successful administration of the first patient in a Phase Ib/II clinical trial for the treatment of recurrent or metastatic triple-negative breast cancer (TNBC) using the bispecific antibody, Opalizumab (LBL-024), which targets PD-L1 and 4-1BB [1] Group 1: Clinical Trial and Drug Development - The Phase Ib/II clinical trial is an open-label, multicenter study led by Professor Yin Yongmei from Jiangsu Provincial People's Hospital, aiming to evaluate the efficacy and safety of Opalizumab alone or in combination with albumin-bound paclitaxel for TNBC patients [1] - Opalizumab is the first bispecific antibody targeting both PD-L1 and 4-1BB, showing potential as a leading therapy for advanced pulmonary neuroendocrine carcinoma and demonstrating promising clinical activity in various indications [1][2] - The drug has received several regulatory designations, including Breakthrough Therapy Designation (BTD) from the NMPA in October 2024 and Orphan Drug Designation from the FDA in November 2024 for neuroendocrine carcinoma [2] Group 2: Market Need and Cancer Statistics - Cancer remains a leading cause of morbidity and mortality globally, with breast cancer being the second most common cancer, accounting for approximately 2.3 million new cases annually [3] - In China, the incidence of breast cancer continues to rise, with an estimated 360,000 new cases and 75,000 deaths each year, highlighting the urgent need for effective treatments, particularly for TNBC, which represents 15% to 20% of all breast cancer cases [3] - TNBC is characterized by high malignancy, recurrence rates, and poor prognosis, indicating a significant unmet clinical need for more effective treatment options beyond standard chemotherapy [3]

Core Insights - The global MCE (Myeloid Cell Engager) market has surpassed $9 billion in cumulative transaction value from 2022 to 2025, with major pharmaceutical companies like Novartis, Eli Lilly, and GSK actively entering the field through collaborations and acquisitions [1][20] - The year 2025 is anticipated to be a pivotal year for MCE, with significant deals such as Sanofi's $1.9 billion acquisition of Dren Bio and GSK's collaboration with LTZ Therapeutics valued at over $1.5 billion [1][19][12] - Despite the enthusiasm from large pharmaceutical companies, there are only a handful of biotech firms with a clear focus on MCE, raising questions about the early-stage technology and the limited number of players in the field [1][20] Industry Dynamics - The bottleneck in immunotherapy has led to a renewed focus on myeloid cell therapies, as traditional T-cell therapies face limitations in solid tumors [2][22] - Research indicates that myeloid cells, such as macrophages and dendritic cells, play a crucial role in the immune response within the tumor microenvironment, prompting a shift towards targeting these cells for therapeutic purposes [2][3] - The MCE approach utilizes bispecific antibodies to bridge tumor cells and myeloid cells, enhancing the immune response against tumors while addressing the limitations of T-cell therapies [5][7] Competitive Landscape - The MCE market is characterized by a three-tier structure: core biotech firms with proprietary technology, multinational corporations (MNCs) accelerating development through partnerships, and companies with foundational immunology expertise poised to enter the market [9][10] - Key players in the biotech sector include Dren Bio, which focuses on Dectin-1 activation, and LTZ Therapeutics, which employs a dual-pathway activation strategy involving myeloid and NK cells [10][11] - Companies like Elpiscience and Glenmark are also exploring innovative approaches to enhance myeloid cell engagement, indicating a diverse range of strategies within the MCE landscape [14][17] Market Potential - The demand for MCE therapies is driven by the substantial market size in oncology and autoimmune diseases, with the global solid tumor treatment market projected to reach $272 billion by 2032 [22] - MCE therapies are expected to address unmet needs in solid tumors, offering a differentiated mechanism compared to traditional therapies, which often face safety and efficacy challenges [22][23] - The potential for MCE to complement existing therapies like CAR-T and PD-1 inhibitors highlights its strategic importance in the evolving landscape of immunotherapy [23][24] Future Outlook - The success of MCE as a next-generation immunotherapy will depend on clinical trial outcomes and the ability to overcome technical challenges related to safety and efficacy [22][24] - The next 3-5 years will be critical for MCE, as clinical data will determine its viability and potential to reshape treatment paradigms in oncology and beyond [24]

撰文丨王聪 编辑丨王多鱼 排版丨水成文 在对抗癌症的战争中，我们身体的免疫系统本是强大的盟友。化疗和免疫疗法等治疗手段，一个重要目的 就是重新唤醒并武装这个盟友，去攻击肿瘤细胞。然而，现实往往很残酷：许多患者最初对治疗有效，但 随着时间推移，肿瘤会产生耐药性，导致治疗失败、肿瘤复发。 这背后，是肿瘤细胞在不断地学习和进化，从而"伪装"自己，逃逸免疫系统的追杀。然而，其中的 潜在机 制，在很大程度上仍不为人知。 2026 年 1 月 26 日， 武汉大学 蓝柯 教授团队 （ 蓝柯教授 、 邬开朗副教授 、 祝成亮 主任技师 为论文 共同通讯作者 ； 武汉大学田明富博士、刘思雨博士研究生、李旭博士为论文共同第一作者 ） 在 Vita 期刊 发表了题为： PNPT1-mtRNA axis mediates chemotherapy-induced immune signaling and can be targeted to overcome therapeutic resistance 的研究论文。 该研究系统揭示了 线粒体 RNA （mtRNA） 衍生的 危险信号 在激活 天然 免疫 和 抗肿瘤治疗中的关键作 ...

Investment Rating - The report initiates coverage on Zai Lab with a "Buy" rating and a target price of RMB 166.16 [1][6] Core Insights - Zai Lab is a leading player in the TCE (T cell engager) field, with its flagship product ZG006 (DLL3/DLL3/CD3) expected to achieve a domestic peak sales of over RMB 4 billion and an overseas peak of nearly USD 6 billion [2][19] - The company has four innovative drugs already approved for sale in China, providing a sustainable cash flow to support early-stage R&D pipelines [1][15] - Zai Lab has partnered with AbbVie to expand ZG006 into international markets, which is anticipated to accelerate clinical progress and enhance market penetration [2][19] Summary by Sections Investment Rating - The report assigns a "Buy" rating to Zai Lab with a target price of RMB 166.16 [1][6] Market Potential - ZG006 is projected to have a domestic peak sales of over RMB 4 billion and an overseas peak of nearly USD 6 billion, driven by the high unmet medical need in small cell lung cancer (SCLC) [2][19] - The report highlights the potential for ZG006 to achieve a significant market share in the first-line SCLC treatment, with expectations of a 30% peak market share due to AbbVie's commercialization capabilities [5][19] Product Pipeline - Zai Lab has a robust pipeline with multiple innovative drugs, including ZG005 (PD-1/TIGIT) and ZGGS34 (MUC17/CD3/CD28), which are in various stages of clinical trials [4][22] - The company has successfully commercialized four innovative drugs, including Donafenib, which generated approximately RMB 530 million in sales in 2024 [3][15] Financial Projections - The report forecasts Zai Lab's revenue to grow from RMB 843 million in 2025 to RMB 2.22 billion in 2027, with a projected net profit of RMB 5.46 million in 2025 [6][10] - The DCF valuation method estimates a target market capitalization of RMB 43.98 billion, corresponding to the target price of RMB 166.16 [6][10]

Investment Rating - The report does not explicitly provide an investment rating for the rare disease industry. Core Insights - The rare disease sector is characterized by significant policy evolution and market trends, with a focus on the accessibility of treatments and the development of orphan drugs [1][2][5]. Summary by Sections Overview of the Rare Disease Industry - The report analyzes the policies regarding rare diseases in China, the United States, Japan, and Europe, highlighting the differences in definitions and management frameworks across these regions [6][12]. - China has included 207 diseases in its rare disease directory, while the U.S. has no unified directory but manages information through the GARD database [10][11]. Patient Population and Management Status - The report indicates that rare diseases affect over 200 million people globally, with China having more than 20 million affected individuals [12][14]. - The management systems in China are still developing, with significant gaps in data accuracy and epidemiological tracking compared to established systems in the U.S. and Europe [13][14]. Drug Availability and Accessibility - As of 2024, China has approved 55 rare disease drugs, while the U.S. has approved 26, and the EU has approved 15 [15][16]. - The report notes that 70.5% of rare diseases globally have available treatments, but many patients in China still face challenges in accessing these medications due to high costs and limited insurance coverage [16][17]. Leading Companies in Rare Disease Drug Development - The report identifies key players in the rare disease drug development space, emphasizing the growing pipeline of domestic research in China, although it still lags behind international pharmaceutical companies in innovation [16][17].